Purpose: To test for an association between in vitro fibroblast radiosensit
ivity and complication risk in a case-control study of breast cancer patien
ts treated under standard conditions in a clinical trial of radiotherapy do
se fractionation.
Patients and methods: A cohort of patients participating in a randomised cl
inical trial of radiotherapy dose fractionation was selected on the basis o
f treatment-induced changes in the breast several years later. Thirty-nine
cases with marked normal tissue changes were matched on several variables w
ith 65 controls with no changes attributable to radiotherapy. Dermal fibrob
last strains were established from duplicate skin biopsies, and clonogenic
cell survival assays performed in triplicate after both high (similar to 1.
6 Gy/min) and low (similar to 1 cGy/min) dose-rate irradiation. Laboratory
studies were blind to patient identity, treatment outcome and radiotherapy
schedule.
Results: Analysis of 1128 clonogenic survival curves confirmed significant
inter-patient variation in fibroblast radiosensitivity as measured by clono
genic survival. However, no association between fibroblast radiosensitivity
and the development of late radiotherapy normal tissue effects was detecte
d.
Conclusions: Inter-individual variation in cellular radiosensitivity may no
t be the main determinant of complication risk in patients undergoing radio
therapy for breast cancer. Other biological and technical factors may be mo
re important in explaining the marked interpatient differences in normal ti
ssue damage evident several years after curative radiotherapy. (C) 2000 Els
evier Science Ireland Ltd. All rights reserved.